New live bacterial product for stubborn superbug improves quality of life Microbiome therapeutic tackles C. diff, the most common health care-associated infectious agent in the US. Date: January 31, ...

C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal ...

Clostridioides difficile (C. diff) is a stealthy threat. It infects more than 500,000 people in the United States each year, and kills up to 30,000. It is a leading cause of health-care-associated ...

Iron storage "spheres" inside the bacterium C. diff—the leading cause of hospital-acquired infections—could offer new targets for antibacterial drugs to combat the pathogen. A team of Vanderbilt ...

Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...